Bacterial whole genome sequencing helps to improve our understanding of epidemiology and pathogenesis of bacterial infections and allows comprehensive investigation on virulence, evolution and resistance mechanisms. Nepal, in recent times, has seen some increase in sequencing capabilities but faces numerous hurdles for optimum utilization. However, these hurdles can be alleviated with use of Illumina iSeq100. Therefore, this study aimed at performing whole genome sequencing of bacteria isolated utilizing the iSeq100 platform. For this study, 6 banked Salmonella enterica serovar Typhi bacterial isolates were selected. These isolates were extracted for DNA, confirmed by qPCR and then, their libraries were prepared. The libaries were checked and loaded in Illumina iSeq100 at loading concentration of 200pM. The consensus was generated from the raw genomic data by reference-based assembly, mapping onto S. Typhi CT18. These consensus genomes and coverage parameters were compared to data from using HiSeq. The raw reads were also evaluated using pathogenwatch (v22.3.8) to observe for genotype, mutations and resistance genes. The coverage parameters (coverage width and depth) of the genomes from this study were compared to same genomes sequenced using Illumina HiSeq. The average coverage width (96.81%) and depth (63.75x) of genomes sequenced in iSeq100 were comparable to that of HiSeq (width: 98.72% and depth: 69.87x). When the genomes sequenced from Illumina iSeq100 and HiSeq were compared, the genotypes detected, number of SNPs and genetic determinants of AMR genes were identical. The data from bacterial whole genome sequencing using the Illumina iSeq100 is equally informative when compared to other high-end sequencers. Therefore, the primary goal of this study is to advocate for optimum utlisation of iSeq100 while still ensuring a high standard of quality. This optimum utilization will create capacity to fill critical surveillance gaps.

The authors have declared no competing interest.

This study was independently funded and supported by Center for Infectious Disease Research and Surveillance, Dhulikhel Hospital Kathmandu University Hospital.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study investigated banked bacterial isolates and did not contact human subjects or obtain data associated with them. The ethical approval was obtained from Institutional Review Committee at Kathmandu University School of Medical Sciences.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The raw reads are available as an NCBI BioProject PRJNA1110744 (Accession: SRX24530188 to SRX24530193)